BioLife Solutions Receivables 2010-2025 | BLFS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioLife Solutions receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioLife Solutions receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$229.7B
Boston Scientific (BSX)	$155.9B
Stryker (SYK)	$147.1B
EssilorLuxottica (ESLOY)	$145.9B
Medtronic (MDT)	$116.8B
Lonza Group Ag (LZAGY)	$49.2B
Haleon (HLN)	$44B
ResMed (RMD)	$42.2B
GE HealthCare Technologies (GEHC)	$33.4B
Agilent Technologies (A)	$33.3B
Terumo (TRUMY)	$27.3B
Koninklijke Philips (PHG)	$26.4B
Insulet (PODD)	$23.1B
Zimmer Biomet Holdings (ZBH)	$20.7B
Smith & Nephew SNATS (SNN)	$16.2B
Baxter (BAX)	$12.2B
Sunny Optical Technology (SNPTF)	$10.8B
Demant (WILYY)	$8.1B
Bio-Rad Laboratories (BIO)	$7.7B
Lantheus Holdings (LNTH)	$4B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Envista Holdings (NVST)	$3.4B
Perrigo (PRGO)	$3.2B
Prestige Consumer Healthcare (PBH)	$3.2B
ICU Medical (ICUI)	$3B
Haemonetics (HAE)	$2.6B
LeMaitre Vascular (LMAT)	$2.2B
Acuren (TIC)	$2.1B
Curaleaf Holdings (CURLF)	$1.9B
Green Thumb Industries (GTBIF)	$1.8B